P08.01 Low-dose checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavourable immunological profile (MSI low, PD-L1 under 1%, TMB low) – A single-institution experience from 2015 to 2020

October 2020, Journal for ImmunoTherapy of Cancer 8(Suppl 2):A49.2-A50

(DOI:10.1136/jitc-2020-ITOC7.97)